

April 15, 2024

Call for Expressions of Interest Research Grants for Classical Homocystinuria

HCU Network America and HCU Network Australia established a research grant program and a Scientific Advisory Board (SAB) in 2017 to identify and advise on research priorities focused on homocystinuria related to CBS Deficiency. Four grants have been awarded from 2018 through 2023. This fourth call is being initiated for Expressions of Interest (EOI) to identify a small number of potential researchers whose programs will be considered for grants and invited to submit a Grant Application.

Eligible Applicants

Eligible applicants must have a Ph.D., M.D., or equivalent degrees and currently hold a full-time position at any level (post-doctoral, research scientist, assistant/associate/full professor, etc.) at an established academic/research institution. Applicants will be considered from the United States and internationally.

Key Priorities

Key priorities for EOIs to be considered should include one of the following:

- New therapies to treat classical homocystinuria by exploring novel mechanisms to obtain proof of concept to enable progression to clinical trials
- Implications of homocystinuria at a molecular level, with focus on venous thrombosis

Awards are expected to be up to \$50,000; however exceptional applications may be funded at a higher amount if the budget request is justified. The award requires that funds not be used for the support of institutional indirect or overhead costs. Research Grants are intended to support projects to produce proof of concept that would facilitate more substantial funding from federal agencies, foundations or corporations.

Expression of Interest

Researchers are asked to submit an Expression of Interest (EOI) Application including high level description of the proposed project, potential budget range and any conflict of interests with SAB members (see list below).

EOI required details include:

- Project Title
- Principal Investigator Name
- Abstract/Summary of Project no more than 350 words
- Hypothesis to be tested
- Significance of proposed research
- Project timeline (assuming project start March 1, 2025) with 12 month duration to February 28, 2026)
- Project Budget (budget range is acceptable for EOI)

Please submit Expressions of Interest by June 15, 2024 following this link to a Microsoft form submission https://forms.office.com/r/GYMzSa2Pat. If you are having trouble with this link, please email Margie McGlynn at grants@hcunetworkamerica.org.

EOIs will be reviewed by the SAB, in consultation with HCU Network America, and applicants will be notified by August 15, 2024 if they are invited to submit a Grant Application.

For additional information on the research strategy and application process for this grant program please visit:

https://hcunetworkamerica.org/classical-hcu-research/global-grants-program/

Potential conflicts

An affiliation with one or more of the SAB members is considered a conflict of interest and must be noted in the application. SAB members are listed below.

Scientific Advisory Board members:



Warren Kruger, (Chair of SAB); Ph. D, Full professor, Cancer Biology program at Fox Chase Cancer Center, Philadelphia, PA, U.S.



Andrew Morris, (Co-Chair of SAB); MD, Consultant and Senior Lecturer in Paediatric Metabolic Medicine, Willink Metabolic Unit, Central Manchester University Hospital.



Matthias R. Baumgartner, Prof. Dr. med., head of Division for Metabolic Diseases and Medical Director of the Swiss Newborn Screening Program, Kinderspital, Zürich, Switzerland.



Kaustuv Bhattacharya, MD, Senior Staff Specialist, Sydney Children's Hospitals Network, Sydney, Australia, Conjoint Senior Lecturer, Discipline of Child and Adolescent Health and Genomics, Sydney University.



Kimberly Chapman, MD, Ph.D., attending physician in Genetics and Metabolism, Children's National, Assistant Professor of Pediatrics and Integrated Systems Biology, George Washington University, U.S.



Viktor Kožich, MD, Ph.D, Professor of Medical Genetics, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague and Charles University-First Faculty of Medicine, Prague, Czech Republic.

Patient Representatives:



Margaret McGlynn, R. Ph., Hon D Sc, President of Board, HCU Network America



Tara Morrison, BA LLB, Director and Chair, HCU Network Australia